## Osama Saher

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8754003/publications.pdf

Version: 2024-02-01

		1478505	1474206	
9	212	6	9	
papers	citations	h-index	g-index	
9	9	9	328	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Quantification of extracellular vesicles <i>in vitro</i> and <i>in vivo</i> using sensitive bioluminescence imaging. Journal of Extracellular Vesicles, 2020, 9, 1800222.	12.2	114
2	Growth Media Conditions Influence the Secretion Route and Release Levels of Engineered Extracellular Vesicles. Advanced Healthcare Materials, 2022, 11, e2101658.	7.6	28
3	Novel peptide-dendrimer/lipid/oligonucleotide ternary complexes for efficient cellular uptake and improved splice-switching activity. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 132, 29-40.	4.3	17
4	Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects. Blood Advances, 2020, 4, 2439-2450.	5.2	15
5	Oligonucleotide–Palladacycle Conjugates as Splice-Correcting Agents. Molecules, 2019, 24, 1180.	3.8	10
6	Sugar and Polymer Excipients Enhance Uptake and Splice-Switching Activity of Peptide-Dendrimer/Lipid/Oligonucleotide Formulations. Pharmaceutics, 2019, 11, 666.	4.5	10
7	Novel endosomolytic compounds enable highly potent delivery of antisense oligonucleotides. Communications Biology, 2022, 5, 185.	4.4	7
8	Novel Orthogonally Hydrocarbon-Modified Cell-Penetrating Peptide Nanoparticles Mediate Efficient Delivery of Splice-Switching Antisense Oligonucleotides In Vitro and In Vivo. Biomedicines, 2021, 9, 1046.	3.2	6
9	Lipophilic Peptide Dendrimers for Delivery of Splice-Switching Oligonucleotides. Pharmaceutics, 2021, 13, 116.	4.5	5